CA3114021C - METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE - Google Patents

METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE

Info

Publication number
CA3114021C
CA3114021C CA3114021A CA3114021A CA3114021C CA 3114021 C CA3114021 C CA 3114021C CA 3114021 A CA3114021 A CA 3114021A CA 3114021 A CA3114021 A CA 3114021A CA 3114021 C CA3114021 C CA 3114021C
Authority
CA
Canada
Prior art keywords
beta
hydroxypropyl
cyclodextrin
cyclodextrin composition
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3114021A
Other languages
English (en)
French (fr)
Other versions
CA3114021A1 (en
Inventor
Sharon H. Hrynkow
Jeffrey L. Tate
Scott Fine N.
Original Assignee
Cyclo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclo Therapeutics Inc filed Critical Cyclo Therapeutics Inc
Publication of CA3114021A1 publication Critical patent/CA3114021A1/en
Application granted granted Critical
Publication of CA3114021C publication Critical patent/CA3114021C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
CA3114021A 2018-10-29 2019-10-24 METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE Active CA3114021C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862752131P 2018-10-29 2018-10-29
US62/752,131 2018-10-29
US201962885053P 2019-08-09 2019-08-09
US62/885,053 2019-08-09
PCT/US2019/057784 WO2020092107A1 (en) 2018-10-29 2019-10-24 Methods for treating alzheimer's disease

Publications (2)

Publication Number Publication Date
CA3114021A1 CA3114021A1 (en) 2021-05-07
CA3114021C true CA3114021C (en) 2025-05-27

Family

ID=68583503

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3114021A Active CA3114021C (en) 2018-10-29 2019-10-24 METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE

Country Status (10)

Country Link
US (3) US11925659B2 (https=)
EP (1) EP3873604B1 (https=)
JP (1) JP7446322B2 (https=)
KR (1) KR20210084480A (https=)
CN (1) CN112996562A (https=)
BR (1) BR112021008139A2 (https=)
CA (1) CA3114021C (https=)
ES (1) ES2992137T3 (https=)
PT (1) PT3873604T (https=)
WO (1) WO2020092107A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US11466008B2 (en) 2017-09-18 2022-10-11 Eip Pharma, Llc Co-crystals of neflamapimod (VX-745)
CN113490691A (zh) 2019-01-03 2021-10-08 劣势者药物有限公司 环糊精二聚体、其组合物及其用途
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
EP4157290A4 (en) * 2020-06-02 2024-06-05 National University of Singapore COMPOSITIONS, THEIR USES IN THERAPY AND METHODS THEREFOR
WO2022051631A1 (en) 2020-09-03 2022-03-10 University Of Notre Dame Du Lac Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
WO2022099094A1 (en) * 2020-11-06 2022-05-12 Eip Pharma, Inc. Compositions and methods for treating depression
EP4240486A4 (en) * 2020-11-06 2024-05-22 EIP Pharma, Inc. TREATMENT OF GALKING DYSFUNCTION IN THE CONTEXT OF A NEURODEGENERATIVE DISEASE
US12285440B2 (en) 2021-03-14 2025-04-29 Massachusetts Institute Of Technology APOE4 impairs myelination via altered cholesterol biosynthesis and transport in oligodendroglia
WO2023089062A1 (en) * 2021-11-18 2023-05-25 Vib Vzw Improved gamma-secretase inhibitor screening assays
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
WO2023191425A1 (ko) * 2022-03-28 2023-10-05 주식회사 비엔에이치리서치 약물의 전기생리학적 스크리닝 방법
CN114569742B (zh) * 2022-05-09 2022-07-19 北京剂泰医药科技有限公司 一种组合物及其制备方法和应用
CA3259307A1 (en) * 2022-06-13 2023-12-21 Beren Therapeutics P.B.C. SYSTEMS AND METHODS FOR MANUFACTURING HYDROXYPROPYL-BETA-CYCLODEXTRIN
EP4561566A1 (en) * 2022-07-29 2025-06-04 Anavex Life Sciences Corp. Compositions and methods for prevention of cognitive decline caused by degenerative diseases
KR20250073473A (ko) * 2022-09-30 2025-05-27 싸이클로 테라퓨틱스, 아이엔씨. 조기 알츠하이머병 치료 방법
WO2025214478A1 (zh) * 2024-04-12 2025-10-16 北京华昊中天生物医药股份有限公司 一种优替德隆药物组合物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4877778A (en) 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US5569756A (en) 1995-03-21 1996-10-29 American Maize-Products Company Purification of chemically modified cyclodextrins
US8883494B2 (en) 2003-11-14 2014-11-11 Adil A. KHAN In vitro model for neuronal death
CN101674842A (zh) 2007-03-02 2010-03-17 普瑞芬医药有限公司 治疗阿尔茨海默氏病和痴呆的组合物和方法
MX371073B (es) 2012-04-13 2020-01-15 L&F Res Llc Método para utilizar ciclodextrina.
CN107865968B (zh) 2012-08-03 2021-03-05 美国政府(由卫生和人类服务部的部长所代表) 用于治疗溶酶体贮积症的环糊精
FR3014694B1 (fr) 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
US10413517B2 (en) 2014-06-12 2019-09-17 University Of Notre Dame Du Lac Composition and method for the treatment of neurological diseases and cerebral injury
WO2016168772A1 (en) 2015-04-17 2016-10-20 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス， インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法
US20200000840A1 (en) * 2016-03-20 2020-01-02 Asdera Llc Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders

Also Published As

Publication number Publication date
CN112996562A (zh) 2021-06-18
EP3873604B1 (en) 2024-08-21
CA3114021A1 (en) 2021-05-07
KR20210084480A (ko) 2021-07-07
BR112021008139A2 (pt) 2021-08-03
WO2020092107A1 (en) 2020-05-07
US20220008453A1 (en) 2022-01-13
JP2022509358A (ja) 2022-01-20
EP3873604A1 (en) 2021-09-08
ES2992137T3 (es) 2024-12-09
JP7446322B2 (ja) 2024-03-08
PT3873604T (pt) 2024-10-22
US11925659B2 (en) 2024-03-12
US20240415871A1 (en) 2024-12-19
US20250302864A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
CA3114021C (en) METHODS OF TREATMENT FOR ALZHEIMER'S DISEASE
US20250114330A1 (en) (3ar)-1,3a,8-trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
HK1242998A1 (zh) 治疗法布里病的给药方案
CA2988529A1 (en) Hydroxypropyl beta-cyclodextrin compositions and methods
KR20150002681A (ko) App 특이적 bace 억제제(asbi) 및 이의 용도
Rainov et al. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate?
EP3445369B1 (en) Vx-745 for use in the treatment of dementia
KR20250078929A (ko) 알츠하이머병 치료를 위한 면역치료법과 사일로이노시톨 병용
WO2024073409A1 (en) Methods for treating early alzheimer's disease
HK40059055B (en) Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin
HK40059055A (en) Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin
Budhwani et al. Exosome-mediated delivery of a PLD1 modulator overcomes bioavailability hurdles to target synaptopathy in neurodegenerative diseases
TW202425995A (zh) 減少與神經退化疾病相關的神經退化的方法
US20260124236A1 (en) Methods for treating early alzheimer’s disease
CA3268619A1 (en) Methods for treating early alzheimer's disease
WO2015198329A1 (en) Injectable formulations for intrathecal administration of antibiotic agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220923

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241018

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241018

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241018

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250306

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250306

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250306

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20250327

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250425

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250425

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250521

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250527

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251017

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251017